KATELYN CLIFTON: Open Payments
NPI 1285173997 · CLAXTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,429 in 113 payments from 31 companies in 2025. Trend: 2023 $1,806 · 2024 $1,323 · 2025 $2,429
Food & beverage: $2,429
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 19 | $287 |
| AstraZeneca Pharmaceuticals LP | 9 | $280 |
| ABBVIE INC. | 14 | $264 |
| Novo Nordisk Inc | 5 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $149 |
| Janssen Pharmaceuticals, Inc | 2 | $140 |
| Lilly USA, LLC | 7 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $110 |
| E.R. Squibb & Sons, L.L.C. | 1 | $103 |
| Corcept Therapeutics | 4 | $91 |
Products named: AIRSUPRA, VRAYLAR, Ozempic, CAPLYTA, SPRAVATO, OTEZLA, REPATHA, REXULTI.
Industry payments across GA — which companies pay providers there.
